• Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E6A20 v3 fusion (PubMed=31882684; PubMed=35933914).
  
• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=35933914).
  
• Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=35933914).
  
• Mutation; HGNC; HGNC:427; ALK; Simple; p.Gly1202Arg (c.3604G>A); ClinVar=VCV000376134; Zygosity=Heterozygous (PubMed=31882684; PubMed=35933914).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=35933914).
  

PubMed=31882684; DOI=10.1038/s41598-019-56356-4; PMCID=PMC6934824
Kim S.-Y., Lee J.Y., Kim D.H., Joo H.-S., Yun M.R., Jung D., Yun J., Heo S.G., Ahn B.-C., Park C.W., Pyo K.H., Chun Y.J., Hong M.H., Kim H.R., Cho B.C.
Patient-derived cells to guide targeted therapy for advanced lung adenocarcinoma.
Sci. Rep. 9:19909-19909(2019)

PubMed=35933914; DOI=10.1016/j.lungcan.2022.07.010
Bokhari A.A.A., Lai W.-Y., Le A.T., Gabre J.L., Chuang T.-P., Fransson S., Bergman B., Djos A., Chen N., Martinsson T., Van den Eynden J., Doebele R.C., Palmer R.H., Hallberg B., Umapathy G.
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Lung Cancer 171:103-114(2022)